financetom
Business
financetom
/
Business
/
Genuine Parts' Outlook 'Too Optimistic,' Q2 Unlikely to Exceed Expectations, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Genuine Parts' Outlook 'Too Optimistic,' Q2 Unlikely to Exceed Expectations, UBS Says
Jul 16, 2025 12:28 PM

03:03 PM EDT, 07/16/2025 (MT Newswires) -- Genuine Parts' ( GPC ) current outlook appears "too optimistic" and the company may lower its guidance to something more achievable, UBS said in a Tuesday note, noting that the company's Q2 results are not likely to exceed expectations.

The company's outlook assumes three positive factors kicking in H2: inflation from tariff-induced inflation, reduced economic uncertainty, and lower interest rates, UBS analysts said. Of the three, only price inflation appears to be happening, they said.

National Automotive Parts Association, a division of the company, is making progress acquiring and integrating its independent operators, but its US segment is losing some market share to O'Reilly Automotive (ORLY) and AutoZone ( AZO ) , the analysts said. This will likely continue until Genuine Parts ( GPC ) gains more control over the stores, they said.

Demand in the industrial segment is still subdued, and an initial positive trend in the first two months of the year may have caused "misplaced optimism" about industrial demand improving in H2, the analysts said.

Overall, the company is fighting to maintain market share across it businesses in North America, and it will need more time and investment to compete with its bigger peers, the analysts said. The stock will likely be range-bound in the near term, they said.

UBS maintained the company's stock rating at neutral and price target at $125.

Price: 122.18, Change: -0.05, Percent Change: -0.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Kootenay Silver Reports First Assays from Ongoing Drilling at Columba Project in Mexico
Kootenay Silver Reports First Assays from Ongoing Drilling at Columba Project in Mexico
Nov 19, 2025
08:40 AM EST, 11/19/2025 (MT Newswires) -- Kootenay Silver ( KOOYF ) released Wednesday assays from the first seven holes of the ongoing 50,000-meter drill program at the Columba silver project in Mexico. The company said drilling identified porphyry style gold mineralization along the I vein. Highlights include 101 meters of 0.18 grams per tonne gold and 10 g/t silver,...
Progressive October Net Income Rises
Progressive October Net Income Rises
Nov 19, 2025
08:40 AM EST, 11/19/2025 (MT Newswires) -- Progressive (PGR) on Wednesday reported October net income of $1.44 per share, up from $0.69 a year earlier. Net premiums earned in October were $7.08 billion, up from $6.39 billion a year earlier. Total companywide policies in force were 38.4 million, up from 34.4 million a year earlier. ...
Blockfusion, Owner-Operator of a Strategically Located Clean Energy-Powered Data Center, to Go Public via Business Combination with Blue Acquisition Corp.
Blockfusion, Owner-Operator of a Strategically Located Clean Energy-Powered Data Center, to Go Public via Business Combination with Blue Acquisition Corp.
Nov 19, 2025
The surge in demand for HPC and AI compute is driving demand for data center capacity across the industry. Blockfusion's Niagara Facility has become a sought-after location for customers pursuing high-density HPC/AI deployments. Blockfusion is responding to this demand by upgrading and expanding an already powered and operational facility into a next-generation data center built for GPU-driven workloads. Blockfusion's owned and...
Moderna to complete US mRNA manufacturing network with $140 million investment
Moderna to complete US mRNA manufacturing network with $140 million investment
Nov 19, 2025
Nov 19 (Reuters) - Moderna ( MRNA ) said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network. The Cambridge-based company plans to invest more than $140 million to add the final manufacturing step to its existing facility in Massachusetts. The move...
Copyright 2023-2026 - www.financetom.com All Rights Reserved